- Home
- FXNC vs CLYM Comparison
FXNC vs CLYM Comparison
Compare FXNC & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FXNC
- CLYM
- Stock Information
- Founded
- FXNC 1907
- CLYM 2018
- Country
- FXNC United States
- CLYM United States
- Employees
- FXNC N/A
- CLYM N/A
- Industry
- FXNC Major Banks
- CLYM
- Sector
- FXNC Finance
- CLYM
- Exchange
- FXNC Nasdaq
- CLYM NYSE
- Market Cap
- FXNC 203.6M
- CLYM 201.7M
- IPO Year
- FXNC N/A
- CLYM 2021
- Fundamental
- Price
- FXNC $22.62
- CLYM $3.05
- Analyst Decision
- FXNC Strong Buy
- CLYM
- Analyst Count
- FXNC 1
- CLYM 0
- Target Price
- FXNC $21.00
- CLYM N/A
- AVG Volume (30 Days)
- FXNC 11.8K
- CLYM 342.1K
- Earning Date
- FXNC 11-01-2024
- CLYM 11-12-2024
- Dividend Yield
- FXNC 2.66%
- CLYM N/A
- EPS Growth
- FXNC N/A
- CLYM N/A
- EPS
- FXNC 1.12
- CLYM N/A
- Revenue
- FXNC $48,807,000.00
- CLYM N/A
- Revenue This Year
- FXNC N/A
- CLYM N/A
- Revenue Next Year
- FXNC $41.13
- CLYM N/A
- P/E Ratio
- FXNC $20.11
- CLYM N/A
- Revenue Growth
- FXNC N/A
- CLYM N/A
- 52 Week Low
- FXNC $14.50
- CLYM $2.35
- 52 Week High
- FXNC $24.59
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- FXNC 60.25
- CLYM N/A
- Support Level
- FXNC $22.45
- CLYM N/A
- Resistance Level
- FXNC $24.59
- CLYM N/A
- Average True Range (ATR)
- FXNC 0.58
- CLYM 0.00
- MACD
- FXNC -0.16
- CLYM 0.00
- Stochastic Oscillator
- FXNC 40.12
- CLYM 0.00
About FXNC First National Corporation
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. Loan products and services include personal loans, residential mortgages, home equity loans, and commercial loans. Deposit products and services include checking and savings. The Bank's wealth management division offers estate planning, investment management of assets, retirement accounts, and estate settlement.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.